GlassScriptPhysician profile
Stephen A Fry
NPI 1659334456
$3,611.42
in general payments reported to CMS, 2019-2025
42 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $208 · 2021: $325 · 2022: $286 · 2023: $707 · 2024: $919 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $719.18 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $690.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $263.33 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $256.92 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.58 | 2020-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $118.55 | 2021 | |
| Amgen INC. | $117.31 | 2019-2024 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $108.41 | 2019-2023 | Gardasil 9, Dificid, Vaxelis |
| Dynavax Technologies Corporation | $89.17 | 2023-2025 | Heplisav-B |
| Amarin Pharma, INC. | $81.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $72.21 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $71.00 | 2022-2024 | Shingrix |
| Xeris Pharmaceuticals, INC. | $64.65 | 2022-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $49.91 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $46.80 | 2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $46.69 | 2023 | Intellis Adaptivestim |
| Corium, LLC | $45.57 | 2023 | Adlarity |
| Irhythm Technologies, INC. | $43.97 | 2024 | Zio Xt Patch, Zio Monitor |
| C2n Diagnostics, LLC | $37.10 | 2025 | Precivityad2 |
| Mylan Specialty L.P. | $32.66 | 2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $32.51 | 2019 | |
| Genzyme Corporation | $30.79 | 2024 | |
| Astellas Pharma US INC | $29.12 | 2023 | Veozah |
| Daiichi Sankyo INC. | $23.86 | 2023 | Injectafer |
| Esperion Therapeutics, INC. | $23.23 | 2025 | Nexletol |
| Antares Pharma, INC. | $22.84 | 2025 | Xyosted |
| Gilead Sciences, INC. | $22.36 | 2019-2020 | |
| Viiv Healthcare Company | $22.04 | 2024 | Apretude |
| Genentech USA, INC. | $21.87 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.57 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $19.57 | 2025 | Thinprep 2000 Processor, Aptima |
| Phathom Pharmaceuticals, INC. | $18.65 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $18.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.30 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.28 | 2024 | Uptravi, Opsumit |
| Tms Neurohealth Centers INC. | $15.41 | 2025 | Tms Neurohealth Centers INC. |
| Lundbeck LLC | $14.78 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $14.75 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sanofi-Aventis U.S. LLC | $14.37 | 2019 | |
| Shield Therapeutics INC | $13.80 | 2023 | Accrufer |
| Eisai INC. | $12.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.